Pfizer submits new drug application to FDA for its COVID-19 treatment Paxlovid
Pfizer announced this morning it submitted a new drug application to formally ask the U.S. Food and Drug Administration for full approval of its COVID-19 treatment Paxlovid for patients who are at high risk for progression to severe illness from the virus.
•
Jun 30, 2022, 11:36 AM
•
Updated 905 days ago
Share:
More Stories
0:21
FDA: More than 2 million cans of Jarritos Coconut Water recalled over seal concerns
19h ago0:51
Party City closing down all of its stores, company says
21h ago2:09
Amazon workers strike for better pay, conditions ahead of holidays
yesterday
Supreme Court will hear arguments over the law that could ban TikTok in the US if it's not sold
2ds ago1:46
Amazon’s Bronx same-day delivery site gears up for holiday rush
4ds ago3:12
be Well: It's not too late to get the hottest toys this holiday season!
5ds ago0:21
FDA: More than 2 million cans of Jarritos Coconut Water recalled over seal concerns
19h ago0:51
Party City closing down all of its stores, company says
21h ago2:09
Amazon workers strike for better pay, conditions ahead of holidays
yesterdaySupreme Court will hear arguments over the law that could ban TikTok in the US if it's not sold
2ds ago1:46
Amazon’s Bronx same-day delivery site gears up for holiday rush
4ds ago3:12
be Well: It's not too late to get the hottest toys this holiday season!
5ds agoPfizer announced this morning it submitted a new drug application to formally ask the U.S. Food and Drug Administration for full approval of its COVID-19 treatment Paxlovid for patients who are at high risk for progression to severe illness from the virus.
The submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals.
Paxlovid is currently authorized for emergency use for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients, 12 years and older, with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
The submission provides the longer-term follow-up data necessary for acceptance and potential approval.
More from News 12
Hometown Heroes in New York City
Nobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
0:21
Biden administration announces $600M to produce COVID tests and will reopen website to order them
1:54
Hochul: Updated COVID vaccine to be available in NY in the coming days
2:22
New and rare COVID variant detected in NYC wastewater; Gov. Hochul urges caution
2:39
